- Postpartum depression (PPD) significantly impacts maternal mental health and can harm the child's growth and development, emphasizing the urgency for effective treatments.
- Traditionally, antidepressants have been the primary treatment for PPD, but recent findings suggest they may not be as effective, highlighting the need for new solutions.
- In 2023, zuranolone received FDA approval as the first oral medication specifically for PPD, offering potential for better treatment outcomes, backed by clinical trials demonstrating its effectiveness.